Sarepta Therapeutics (SRPT) Sees Intra-Day Selling Pressure
- Wall Street dips as investors ready for Trump's inauguration
- Netflix, Inc. (NFLX) Tops Q4 EPS by 1c; Subs Beat Views
- Apple (AAPL) PT Raised to $140 at BofA/Merrill Lynch; iPhone 8 Will be 'Super-Long' Cycle
- Morgan Stanley Upgrades Tesla Motors (TSLA) to Overweight
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) seeing notable intra-day pressure. Shares down 3.2%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) Exondys 51 requires "review of drug and site of care required" at Aetna
- Options with increasing volume
- Perrigo (PRGO) short duration January calls active